Martha Carlin is a transformational leader who has leveraged her extensive business experience as a turnaround expert to become a leading citizen scientist in the field of the microbiome. With a focus on improving human health, Carlin founded The BioCollective, a company dedicated to studying the microbiome and its impact on human health. Through The BioCollective, she has conducted groundbreaking research on the gut microbiome and its relationship to diseases such as Parkinson's. Carlin also launched the BiotiQuest brand of targeted probiotics, which offers customized probiotics based on an individual's microbiome. Her innovative approach has earned recognition from the National Institutes of Health and the Human Microbiome Project, making her a key figure in the field of microbiome research.
THE MICROBIOME: THE ULTIMATE INFORMATION SUPERHIGHWAY
SATURDAY, OCTOBER 21
In this enlightening presentation, Martha Carlin will explore the fascinating world of the microbiome and its profound influence on our overall health. Discover how the trillions of microorganisms living within us form a complex ecosystem that communicates and interacts with our genetic information, impacting various aspects of our well-being.
She will delve into the gut-brain axis and the emerging field of microbial endocrinology, unveiling the intricate ways in which our microbiome communicates with our brain and affects our mental health. Furthermore, she will examine the detrimental impact of glyphosate on the microbiome and minerals and enzymes, and discuss strategies to mitigate its effects.
She will explore the relationship between information and inflammation, shedding light on the concept of "garbage in, garbage out" and how molecular mimicry between microbes and food peptides can contribute to autoimmune diseases.
Lastly, she will explore the power of restoring the gut through fermented foods and targeted probiotics. Clinical evidence demonstrating the positive effects of probiotics on glucose metabolism will be presented, providing valuable insights into potential therapeutic interventions for metabolic disorders.